Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants by Jaehyeon Hwang, Soyun Choi, Beom Kyu Kim, Sumin Son, Jeong Hyeon Yoon, Kyung Won Kim, Wonbeom Park, Hyunjoo Choo, Suhyun Kim, Soomin Kim, Seokhyeon Yu, Sangwon Jung, Sang Taek Jung, Min-Suk Song, Sang Jick Kim, Dae-Hyuk Kweon

“…Notably, Sotrovimab, an FDA-approved monoclonal antibody that has experienced a significant decline in neutralizing potency due to viral evolution, exhibited robust antiviral activity when complexed with the nanodisc against all tested Omicron variants. …”
Get full text

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study by Federico Diotallevi, Giulia Matacchione, Anna Campanati, Elena Marinelli Busilacchi, Nadia Viola, Ilaria Pace, Beatrice Fontana, Roberta Roncarati, Massimiliano Bonafè, Manuela Ferracin, Jacopo Sabbatinelli, Fabiola Olivieri

“…Objectives This study aimed to investigate changes in circulating miRNAs in psoriasis patients undergoing risankizumab therapy, an anti-IL-23 monoclonal antibody, to understand its impact on disease pathogenesis and treatment response. …”
Get full text

Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity by Mariana P. Miranda-Hernández, Carlos A. López-Morales, Nancy D. Ramírez-Ibáñez, Nelly Piña-Lara, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, Emilio Medina-Rivero

“…Rituximab is a chimeric monoclonal antibody employed for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. …”
Get full text

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma by Lawrence G Lum, Parameswaran Hari, Aniko Szabo, Michele Donato, Jee Hyun Park, Daniel H Fowler, Binod Dhakal, Saurabh Chhabra, Deborah D Glass, David S Siegel, Tania C Felizardo

“…RAPA-201 recipients had preservation of T cell counts and Th1 cytokine secretion yet had increased T cell receptor clonality that associates with antitumor responses in the setting of monoclonal antibody checkpoint therapy. RAPA-201 therapy overcomes previous barriers to effective autologous polyclonal T-cell therapy, as it is feasible to manufacture, exquisitely safe to administer, and mediates remission in patients with RRMM.Trial registration number ClinicalTrials.gov: NCT04176380.…”
Get full text

Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients by Iván Ferraz-Amaro, Iván Ferraz-Amaro, Sergio Santos-Concepción, Javier Castro-Hernández, Maria Vanesa Hernández-Hernández, Beatriz Tejera Segura, Cristina Luna, Esmeralda Delgado-Frias, Federico Díaz-González, Federico Díaz-González, Federico Díaz-González

“…BackgroundTocilizumab (TCZ) is a monoclonal antibody that neutralizes interleukin (IL)-6 and is indicated for diseases characterized by markedly elevated inflammatory markers, such as rheumatoid arthritis (RA). …”
Get full text

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults by Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin

“…Nirsevimab, an extended half‐life monoclonal antibody against RSV, is approved in China for the prevention of RSV lower respiratory tract disease in infants; however, global nirsevimab trials did not enroll Chinese infants. …”
Get full text

Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-labe... by Ying Zhu, Jianwei Zhou, Zhigang Zhang, Jiaojiao Zhang, Jing Fei, Xiaoqing Zhu

“…The NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr(NAIVE) study aims to assess the clinical efficacy and safety of NACT in combination with tislelizumab (a monoclonal antibody for programmed cell death protein 1) for advanced EOC.Methods and analysis The NAIVE study is an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial for advanced EOC with the International Federation of Gynaecology and Obstetrics (FIGO) stage IIIc with a Suidan CT score of 3 or greater or a Fagotti laparoscopic score of 8 or greater; or FIGO stage IV. …”
Get full text

A simple, highly sensitive and specific serological test for the detection of antibodies to Varicella-zoster virus (<i>Varicellovirus humanalpha3</i>) by Firaya G. Nagieva, Elena P. Barkova, Olga S. Kharchenko, Alexander V. Sidorov, Galina I. Alatortseva, Bogdan S. Cherepovich, Yulia N. Tarakanova, Olga A. Trubacheva, Evgeny A. Pashkov, Artem A. Rtishchev, Oksana A. Svitich, Vitaly V. Zverev

“…The activity of VZV GP was confirmed in PHAR by an antibody diagnostic assay using formalin-treated sheep erythrocytes sensibilised using monoclonal antibodies to GP E of the “vOka” VZV strain (USA). …”
Get full text

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma... by A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy, R. LeBlanc, K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul, D. Reece

“…This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. …”
Get full text

Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo by Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu

“…Among them, biparatopic antibodies (bpAbs) have shown improved efficacy compared to monoclonal antibody (mAb) combinations in HER2-positive patients. …”
Get full text

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context by Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos

“…Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation. …”
Get full text

Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis by Andrew Thamboo, S. Kilty, I. Witterick, Y. Chan, C. J. Chin, A. Janjua, A. Javer, J. Lee, E. Monterio, B. Rotenberg, J. Scott, K. Smith, D. D. Sommer, L. Sowerby, M. Tewfik, E. Wright, M. Desrosiers

“…Therefore, biologics, monoclonal antibody agents, could be beneficial therapeutic treatments for these patients. …”
Get full text

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study by Prashasti Agrawal, MD, Michael Offin, MD, Victoria Lai, MD, Michelle S. Ginsberg, MD, Prasad S. Adusumilli, MD, FACS, Valerie W. Rusch, MD, Jennifer L. Sauter, MD, Teresa Ho, BS, Phillip Wong, PhD, Marjorie G. Zauderer, MD

“…Methods: To further enhance immunogenicity, we combined GPS with nivolumab, an anti-PD1 monoclonal antibody, in an open-label, single-center phase 1 study, examining tolerability and immunogenicity in patients with previously treated DPM. …”
Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

“…Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.Given the limited efficacy of pharmacological treatments, particularly for the recurrent disease, several molecularly targeted interventions have been explored, such as small-molecule protein kinase inhibitors (PKIs), inhibiting tyrosine kinase growth factor receptors and downstream signaling pathways involved in GBM angiogenesis and infiltrative behavior.This meta-analysis, based on searches in PubMed and Web Of Science, evaluated 12 randomized controlled trials (RCTs) examining PKIs in patients with newly diagnosed or recurrent GBM. …”
Get full text

EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer by Yongbin Zheng, Dan Song, Ming Guo, Chenhong Wang, Mingzhen Ma, Gongcai Tao, Licui Liu, Xiaobo He, Fengyu Cao, Dan Luo, Qingchuan Zhao, Zhongyuan Xia, Yanxin An

“…Based on these findings, we demonstrated that dual inhibition of NAT10 and EGFR using Remodelin and the EGFR-specific monoclonal antibody cetuximab resulted in improved therapeutic efficacy compared to either drug alone. …”
Get full text

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial by Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, Zoé Tharin, Leila Bengrine, Hélène Bellio, Aurélie Bertaut, Léa Hampe, Susy Daumoine, Emilie Rederstorff, Morgane Peroz, Titouan Huppe, Valentin Derangère, David Rageot, John Simard, Caroline Truntzer, Jean David Fumet, Francois Ghiringhelli

“…XB2001, a fully human monoclonal antibody neutralizing IL-1α, was evaluated for safety and preliminary efficacy with trifluridine/tipiracil (FTD/TPI) and bevacizumab in metastatic colorectal cancer patients previously treated with oxaliplatin- and irinotecan-based chemotherapies. …”
Get full text

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study by Mohammed Hasosah, Ghassan Sukkar, Asharf AlSahafi, Ali Zaidan, Nouf Ghous, Abdulmajed Alshahrani, Ziyad Al Zahrani, Naif Hasosah, Mansour Qurashi, Loie Goronfolah, Ali Alsharief, Nagla Kamal

“…Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling. …”
Get full text

IL-6/GATA2/SERPINE1 pathway is implicated in regulating cellular senescence after acute kidney injury by Hongshuang Su, Xiaoxi Lin, Ayinuer Paredong, Ayinuer Paredong, Congcong Yao, Yan Zhang, Mengke Geng, Yuqian Guan, Lichao Gong, Feng Jiang, Qi Lv, Songtao Shou, Heng Jin

“…Tocilizumab (TCZ), a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor, is a key substance. …”
Get full text

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy by Xin Liu, Yang Du, Ningyan Zhang, Zhiqiang An, Wei Xiong, Yixiang Xu, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Tianhao Duan, Helen Y Wang, John S. Yu, Rongfu Wang

“…In vivo antitumor activity was investigated in a triple-negative breast cancer (TNBC) model and primary melanoma tumor model in immunocompromised mice.Results Monoclonal antibody 2D2 identified from phage-displayed library specifically bound to NY-ESO-1157-165 in the context of human leukocyte antigen HLA-A*02:01 but not to non-A2 or NY-ESO-1 negative cells. …”
Get full text

Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a m... by Ernest Choy, Kerenza Hood, Emma Thomas-Jones, Eleanor Barnes, Keith Wilson, Christian H Ottensmeier, Debbie Harris, Adrian Hill, Mark Tuthill, Richard Adams, Catherine Porter, Katie Ewer, Sian Griffin, Rebecca Tangney, Joanne Euden, Shirley Pringle, Lawrence Raisanen, Ruby Ray, Lisette Sheena Nixon, Melanie Varley, Craig Bodman, Paola Cicconi, Vivien Dagley, Steven Knapper

“…AZD7442 (Evusheld) is a long-acting monoclonal antibody treatment that has been shown in clinical trials to prevent SARS-CoV-2 infection for up to a year after a single dose. …”
Get full text